₹ 1.0 Cr
Volume transacted
84.1 K
stocks traded
Last Updated time: 25 Jul 9.00 AM
Bliss GVS Pharma Ltd
NSE: BLISSGVS
PE
12.2
Last updated : 25 Jul 9.00 AM
The P/E Ratio of Bliss GVS Pharma Ltd is 12.2 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Bliss GVS Pharma Ltd changed from 15 on March 2019 to 15.6 on March 2024 . This represents a CAGR of 0.66% over 6 years. a1#The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 119.2 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1856 crore on March 2019 to ₹ 1179 crore on March 2024 . This represents a CAGR of -7.28% over 6 years. a1#The Revenue of Bliss GVS Pharma Ltd changed from ₹ 195.67 crore to ₹ 187.77 crore over 9 quarters. This represents a CAGR of -1.81% a1#The EBITDA of Bliss GVS Pharma Ltd changed from ₹ 45.86 crore to ₹ 38.45 crore over 9 quarters. This represents a CAGR of -7.53% a1#The Net Pr of Bliss GVS Pharma Ltd changed from ₹ 27.48 crore to ₹ 22.11 crore over 9 quarters. This represents a CAGR of -9.21% a1#The Dividend Payout of Bliss GVS Pharma Ltd changed from 13.85 % on March 2019 to 10.34 % on March 2024 . This represents a CAGR of -4.75% over 6 years. a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
Mar '19 | 15 |
Mar '20 | 10.7 |
Mar '21 | 14.9 |
Mar '22 | 53.1 |
Mar '23 | 10.5 |
Mar '24 | 15.6 |
Market Cap
₹ 1,250 Cr
EPS
₹ 9.8
P/E Ratio (TTM) *
12.2
P/B Ratio (TTM) *
1.3
Day’s High
₹ 124.55
Day’s Low
₹ 118.35
DTE *
0.1
ROE *
9.9
52 Week High
₹ 148.95
52 Week Low
₹ 77.65
ROCE *
14.3
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
Bliss GVS Pharma Ltd
NSE: BLISSGVS
PRICE
₹ 119.2
-1.80 (-1.49%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
2
S
Weakness
1
W
Opportunity
0
O
Threats
1
T
Market Value
₹ 1,250
Asset Value
₹ 835
0.5 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Bliss GVS Pharma Ltd | 12 | 1,250 |
Sun Pharmaceuticals Industries Ltd | 40 | 399,537 |
Zydus Lifesciences Ltd | 31 | 121,312 |
Cipla Ltd | 28 | 121,120 |
Divis Laboratories Ltd | 75 | 120,782 |
Dr Reddys Laboratories Ltd | 20 | 114,348 |
Earnings
₹81 Cr
12.2 X
PE Ratio
Market Cap
₹1250Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹81 Cr
12.2 X
PE Ratio
Market Cap
₹1250Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 1856 |
Mar '20 | 1040 |
Mar '21 | 1018 |
Mar '22 | 798 |
Mar '23 | 742 |
Mar '24 | 1179 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 196 |
Sep '22 | 175 |
Dec '22 | 211 |
Mar '23 | 188 |
Jun '23 | 165 |
Sep '23 | 224 |
Dec '23 | 206 |
Mar '24 | 204 |
Jun '24 | 188 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 46 |
Sep '22 | 27 |
Dec '22 | 53 |
Mar '23 | 9 |
Jun '23 | 29 |
Sep '23 | 67 |
Dec '23 | 49 |
Mar '24 | 5 |
Jun '24 | 38 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 27 |
Sep '22 | 16 |
Dec '22 | 30 |
Mar '23 | 3 |
Jun '23 | 14 |
Sep '23 | 43 |
Dec '23 | 29 |
Mar '24 | -5 |
Jun '24 | 22 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 14 |
Mar '20 | 6 |
Mar '21 | 8 |
Mar '22 | 6 |
Mar '23 | 6 |
Mar '24 | 10 |
* All values are a in %
Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India. The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India. Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR). During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana. During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent. During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017, The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts. During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth. As on 31 March 2019,the company has one domestic and 3 overseas subsidiaries. During the FY2020,the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state-of-the-art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company. The Company has 4 wholly owned subsidiaries and 3 step-down subsidiaries as on 31 March 2020. During the year, ECO Rich Cosmetics India Private Limited discontinued or ceased to be a step-down subsidiary of the Company consequent to loss of control. The Company's wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 2019-2020.
Bliss GVS Pharma to convene board meeting
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2...
Read more
18 Jul 202411:35
Bliss GVS Pharma to convene AGM
Bliss GVS Pharma announced that the 39th Annual General Meeting(AGM) of the company will b...
Read more
04 May 202416:04
Board of Bliss GVS Pharma recommends final dividend
Bliss GVS Pharma announced that the Board of Directors of the Company at its meeting held ...
Read more
03 May 202410:36
Bliss GVS Pharma announces board meeting date
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 2 May 202...
Read more
26 Apr 202411:02
Bliss GVS Pharma to discuss results
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 23 Januar...
Read more
17 Jan 202411:25
Bliss GVS Pharma to discuss results
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 1 Novembe...
Read more
26 Oct 202315:28
FAQs for PE of Bliss GVS Pharma Ltd
What is Bliss GVS Pharma Ltd current share price?
What is Bliss GVS Pharma Ltd's market cap?
What are Bliss GVS Pharma Ltd's total net assets?
Is Bliss GVS Pharma Ltd making a profit or loss?
Unlimited trading at just
Rs. 199